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2
mental time, provide a much more controllable environment,
and reduce loss of animal life. The present invention seeks to
fulfill this need and provides further related advantages.

CHTOSAN-ALGINATE SCAFFOLD CELL
CULTURE SYSTEMAND RELATED
METHODS

SUMMARY OF THE INVENTION

CROSS-REFERENCE TO RELATED
APPLICATION

This application claims the benefit of U.S. patent applica
tion Ser. No. 61/478,429, filed Apr. 22, 2011, expressly incor
porated herein by reference in its entirety.

The present invention provides methods for culturing can
cer cells in vitro using a three-dimensional scaffold, Scaffolds
that include cultured cancer cells, and methods for using the
10

STATEMENT OF GOVERNMENT LICENSE
RIGHTS

This invention was made with Government support under
EEC9529161 awarded by the National Science Foundation,
and

under

R01EB006043,

RO1CA134213,

15

and

T32CA138312 awarded by the National Institutes of Health.
The Government has certain rights in the invention.

cultured cancer cells and the scaffolds that include cultured

cancer cells in anticancer therapeutic drug development.
In one aspect, the invention provides a method for culturing
cancer cells in vitro. In the method, a porous chitosan-algi
nate scaffold is seeded with cancer cells to provide a scaffold
comprising cancer cells and then the seeded cancer cells are
cultured in the scaffold for a time sufficient to provide a
scaffold comprising cultured cancer cells. In one embodi
ment, the cultured cancer cells comprise tumor spheroids.
In another aspect of the invention, a scaffold comprising
cultured cancer cells is provided.
In one embodiment, the scaffold is a three-dimensional

BACKGROUND OF THE INVENTION

scaffold, comprising a porous chitosan-alginate scaffold and
In vitro studies are an essential component of the initial
screening for any anti-cancer therapy, allowing for high
throughput, cost-efficient exploration of potential therapeu

cultured cancer cells.

In one embodiment, the scaffold is produced by the method
25

tics. However, traditional in vitro cell culture on two-dimen

sional (2D) tissue culture substrates fails to simulate the
structure of the tumor microenvironment (TME) present in
Vivo (i.e., complex cell-cell organization and extracellular
matrix (ECM)-cell interactions, which have significant
effects on cell phenotype and malignancy). Cells in 2D cul
ture are forced to adhere to a rigid surface and are geometri
cally constrained, adopting a flat morphology which alters the
cytoskeleton regulation that is important in intracellular sig
naling, and consequently can affect cell growth, migration,
and apoptosis. Moreover, organization of the ECM, which is
essential to cell differentiation, proliferation, and gene
expression, is absent in 2D cultured tumor cell models. These
limitations of 2D cultures often result in biological responses
to drugs and potentially curative treatments in vitro strikingly

In certain of the above embodiments, the cultured cancer

30
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different from what is observed in vivo. The ideal in vitro

TME model should provide a platform for in vitro drug
screening that will better translate to in vivo testing by mim
icking both the spatial arrangement of cells and ECM signal
ing found in tumors in Vivo, resulting in the expression of the
native in Vivo phenotype in these cells.

of the invention.

cells comprise tumor spheroids.
In another embodiment, the invention provides an in vitro
cancerous tumor model. In the model, cancerous tumor sphe
roids are contained in a three-dimensional scaffold compris
ing chitosan and alginate.
In certain embodiments, cultured cells produced by the
methods of the invention and provided in the chitosan-algi
nate scaffolds of the invention have increased tumor malig
nancy compared to two-dimensionally cultured cancer cells,
increased expression of growth factors compared to two
dimensionally cultured cancer cells, increased expression of
the enzyme MMP-2 compared to two-dimensionally cultured
cancer cells, increased expression of the extracellular matrix
proteins compared to two-dimensionally cultured cancer
cells, increased tumorigenicity in vivo compared to two-di
mensionally cultured cancer cells, and/or increased CD31'
cell recruitment in vivo compared to two-dimensionally cul
tured cancer cells.

45

In a further aspect, the invention provides a method for
producing a cancerous tumor in a Subject. In the method,

Often in vitro results often do not translate well to in vivo

cultured cells obtained from the method of the invention for

systems. As a result, costly in vivo animal models remain the
most sophisticated and faithful models of the disease. The
development of anticancer drugs has been hindered by the
lack of effective tumor models that closely mimic the human

culturing cancer cells or cultured cells from a scaffold of the
invention that includes cultured cancer cells are implanted in
the Subject. In one embodiment, implanting cultured cells
comprises implanting a scaffold of the invention comprising

50

disease.

cultured cancer cells.

Three-dimensional (3D) culture systems are designed to
bridge the gap between in vitro and in Vivo cancer models.
These 3D Systems are intended to increase cancer cell malig
nancy and retain the in vivo phenotype by mimicking the

In another aspect of the invention, a method for Screening
a candidate chemotherapeutic agent in vitro is provided. In
55

structure of the tumor microenvironment. Natural extracellu

lar matrix materials such as collagen, fibrin, and the commer
cially available Matrigel matrix (BD Biosciences) have been
used, but these animal-source products are expensive, and can
potentially transmit pathogens. Synthetic polymers such as
poly(lactide-co-glycolide) (PLGA) have also been studied,
but they can release acidic degradation products that are toxic
to cells, and negatively affect experimental results.
A need exists for improved in vitro models of human can
cer that will allow researchers to reduce in vivo experiments
by in vitro pre-testing that will defray costs, shorten experi

60
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the method, cultured cells obtained from the method of the

invention for culturing cancer cells are contacted with a can
didate chemotherapeutic agent. In one embodiment, contact
ing cultured cells obtained from the method of the invention
for culturing cancer cells comprises contacting the candidate
chemotherapeutic agent with the scaffold of the invention
comprising cultured cancer cells. In certain embodiments, the
method further comprises measuring cell proliferation inhi
bition, measuring the cell viability, and/or measuring protein
expression levels.
In further aspect of the invention, a method for Screening a
candidate chemotherapeutic agent in vivo is provided. In the
method, cultured cells obtained from the method of the inven

US 9,157,908 B2
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tion for culturing cancer cells are implanted in a Subject and a
candidate chemotherapeutic agent is administered to the Sub
ject. In one embodiment, implanting cultured cells obtained
from the method of the invention for culturing cancer cells
comprises implanting the scaffold of the invention compris
ing cultured cancer cells. In the method, administering the
candidate chemotherapeutic drug comprises administering
the drug after a pre-determined period of time. In certain
embodiments, the method further comprises comparing the
tumor mass or Volume measured prior to drug administration
and after a pre-determined period of time after drug admin
istration and/or harvesting the tumor mass after a pre-deter
mined period of time after drug administration and analyzing

4
FIGS. 7A and 7B compare immunohistochemistry of
tumors grown from glioma cells pre-cultured on 2D culture
24-well plates, Matrigel matrix, and CA Scaffolds, respec
tively. C6 (7A) and U-87 MG (7B) tumor sections were
harvested 3 weeks after implantation of the pre-cultured cells,
stained with anti-CD31 to visualize blood vessels (green),
and counterstained with DAPI (blue) with inlays to provide
more details of the blood vessel structure. Scale bars corre
10

the tumor.
15

DESCRIPTION OF THE DRAWINGS

The foregoing aspects and many of the attendant advan
tages of this invention will become more readily appreciated
as the same become better understood by reference to the
following detailed description, when taken in conjunction
with the accompanying drawings, wherein:
FIGS. 1A-1C compare the ability of chitosan-alginate (Ca
lif.) scaffolds to provide a growth environment for tumor cells
in vitro. Proliferation of (1A) C6, (1B). U-87 MG, and (1C)
U-118 MG glioma cells cultured on 2D culture 24-well
plates, Matrigel matrix, and CA Scaffolds, respectively, after
2, 4, 6, 8, and 10 days of cell culture, as determined by the
Alamar Blue viability assay.
FIGS. 2A-2C compare the morphology of (2A) C6, (2B)
U-87 MG, and (2C) U-118 MG glioma cells grown on 2D
culture plates, Matrigel matrix, and CA scaffolds, respec
tively, visualized by SEM imaging. The background is col
ored for enhanced contrast and the scale bar corresponds to 40
lm.

FIGS. 3A-3D compare phenotypic changes in glioma cells
based on in vitro pre-culture conditions, assessed by ELISA
and dot blot analyses. The secretion of (3A) VEGF and (3B)
Matrix metalloproteinase-2 in C6, U-87 MG, and U-118 MG
cells pre-cultured on 2D 24-well culture plates, Matrigel
matrix, and CA Scaffolds, respectively, as determined by
ELISA. Fibronectin (3C) and laminin (3D) secretion in cells
pre-cultured on the three matrices as determined by dot blot
analyses. *, P<0.01; **, P<0.001: ***, P<0.0001, by stu
dent's t-test (N=4).
FIGS. 4A and 4B compare in vivo tumorigenesis of glioma
cells pre-cultured under various in vitro culture conditions.
Growth rates of tumors formed from implants of 2D, Matrigel
matrix, and CA scaffold pre-cultured (4A) C6 or (4B) U-87
MG cells as determined by caliper measurements. *, P<0.01;
**, P<0.001: ***, P<0.0001, by one-way ANOVA (N=6).
FIGS.5A and 5B compare histological analyses of glioma
tumors grown in athymic nude mice 3 weeks after implanta
tion of pre-cultured glioma cells under various in vitro culture
conditions. Masson’s trichrome stained histology slides of
(5A) C6 and (5B) U-87 MG tumors formed from cells pre
cultured on 2D culture 24-well plates, Matrigel matrix, and
CA scaffolds, respectively. Cell nuclei are stained dark red,
cytoplasm is stained light red, connective tissue is stained
dark blue, and Matrigel is stained light blue. Scale bar corre
sponds to 50 Lum.
FIGS. 6A and 6B are images comparing angiogenesis
around tumors formed from glioma cells pre-cultured on 2D
culture 24-well plates, Matrigel matrix, and CA scaffolds,
respectively. Vasculature surrounding (6A) C6 and (6B) U-87
MG tumors were photographed in live, anesthetized mice.
Scale bars correspond to approximately 5 mm.

25

30

35

spond to 100 um and 10 um for the main display and inlay,
respectively.
FIGS. 8A and 8B compare the effect of culture conditions
on hepatocellular carcinoma cell proliferation. Populations of
(8A) PLC and (8B) HepG2 cells cultured for a period of 8
days on 2D plates, Matrigel matrices, and CA Scaffolds,
respectively. Cellular proliferation was determined by the
Alamar Blue assay. Results are shown as meants.d., and *
indicates at least one of the group means is statistically dif
ferent from the others at that time point, p<0.05, n=4.
FIGS. 9A and 9B compare images showing the effect of
culture conditions on hepatocellular carcinoma cell morphol
ogy as observed by SEM. PLC (9A) and HepG2 (9B) cells
were cultured on 2D tissue culture plates, Matrigel matrices,
and CA scaffolds, respectively, for 10 days. The scale bar
represents 10 Lum.
FIGS. 10A-10C compare growth factor expression profiles
of hepatocellular carcinoma cells cultured in vitro for 10
days: (10A) IL-8, (10B) bFGF, and (10C) VEGF secretion by
PCL and HepG2 cells cultured on 2D tissue culture plates,
Matrigel matrices, and CA Scaffolds, respectively, as deter
mined by ELISA. Results are meants.d., and * indicates at
least one of the means in that group is statistically different
from the others, p<0.05, n=4.
FIG. 11 compares glypican-3 (GPC-3) expression by
HepG2 hepatocellular carcinoma cells cultured in vitro for 10
days on 2D tissue culture plates, Matrigel matrices, and CA
scaffolds, respectively, as determined by dot blot analysis.
Results are meants.d., and * indicates at least one of the

40

means is statistically different from the others, p<0.05, n=4.
FIGS. 12A and 12B compare the effect of pre-culture con
ditions on tumor growth in vivo. Tumor volume induced by
subcutaneously implanted (12A) PLC and (12B) HepG2 cells
pre-cultured on 2D tissue culture plates, Matrigel matrices,
and CA Scaffolds, respectively, as determined by caliper mea
Surements. Results are meants.d. and * indicates at least one

45

50

55

of the group means is statistically different from the others at
that time point, p<0.05, n=4.
FIGS. 13A and 13B are images comparing hematoxylin
and eosin stained histological sections of tumors induced by
implanted (13A) PLC and (13B) HepG2 cells pre-cultured on
2D tissue culture plates, Matrigel matrices, and CA scaffolds,
respectively. The implants were harvested 4 weeks post
implantation in nude mice. Nuclei are stained dark purple,
cytoplasm is stained light red, erythrocytes are stained bright
red, and connective tissue is stained pink. Arrows indicate
extravascular erythrocytes. The scale bar represents 20 Lum.
FIGS. 14A and 14B compare drug resistance of hepatocel
lular carcinoma cells cultured under different conditions.

60
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Viability of (14A) PCL and (14B) HepG2 cells cultured on
2D tissue culture plates, Matrigel matrices, and CA scaffolds,
respectively, relative to untreated cells, as determined by the
Alamar Blue assay after doxorubicin treatment. PLC cells
were treated with 5 uM doxorubicin and HepG2 cells were
treated with 10 uM doxorubicin. Results are meants.d., and
indicates at least one of the group means is statistically dif
ferent from the others at that time point, p<0.05, n=4.
FIGS. 15A and 15B compare dose-dependent cytotoxic
response of hepatocellular carcinoma cells to doxorubicin:

US 9,157,908 B2
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they are predisposed to being highly malignant. C6 cells
cultured in the chitosan-alginate scaffold show the unique cell
mass (tumor spheroids) like other less malignant cancer cells.
Although the generation of the tumor spheroid increases
malignancy, the unique matrix/growth environment provided
by the chitosan-alginate scaffold further contributes to malig
nancy. For example, hepatocarcinoma cells cultured in accor

5
(15A) PLC and (15B) HepG2 cells were cultured on 2D tissue
culture plates, Matrigel matrices, and CA Scaffolds, respec
tively, for 10 days before treatment with doxorubicin. Cell
viability relative to untreated cells was determined by the
Alamar Blue assay at 24 h. 48 h and 72 h after doxorubicin
treatment. LDso was calculated based on viability data.
Results are meants.d., and * indicates at least one of the

group means is statistically different from the others at that
time point, p<0.05, n=4.
FIGS. 16A-16C compare the morphology of (16A)
LNCaP (16B) C4-2, and (16C) C4-2B human prostate cancer
cells were grown on 2D culture plates, Matrigel matrices, and
CA scaffolds, respectively, for 15 days before analysis. Scale
bars are 40 um.

dance with the method of the invention, GPC, a biomarker for
10

15

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods for culturing can
cer cells in vitro using a three-dimensional scaffold, Scaffolds
that include cultured cancer cells, and methods for using the
cultured cancer cells and the scaffolds that include cultured

cancer cells in anticancer therapeutic drug development.
As noted above, tumor cells cultured on standard two

dimension (2D) tissue culture flasks are exposed to a dramati
cally altered structural microenvironment as compared to in
Vivo tumors, and thus display altered cell function and
response to drug treatment. The present invention provides an
in vitro model that can more closely mimic the structure of the
tumor microenvironment (TME) and that can dramatically
improve the translation of novel chemotherapeutics from in
vitro to in vivo testing.
In one aspect, the invention provides a method for three

25

30

dimensional cell culture in vitro. In one embodiment, the

method includes seeding a porous chitosan-alginate scaffold
with cancer cells to provide a scaffold comprising cancer
cells; and culturing the cancer cells in the scaffold for a time
Sufficient to provide a scaffold comprising cultured cancer

35

cultured cells.

In the methods of the invention, culture of cancer cells in
40

cells; and the cancer cells seeded in the scaffold are cultured

for a time and under conditions sufficient to provide tumor
spheroids in the scaffold.
As used herein, the term “tumor spheroids’ refers to
spherical, heterogeneous aggregates of proliferating, quies

45

cent, and necrotic cells in culture that retain three-dimen

sional architecture and tissue-specific functions. Tumor sphe
roids represent an in vitro model for studies of the biology of
both normal and malignant cells.
Representative tumor spheroids produced in chitosan-algi
nate scaffolds by the methods of the invention are illustrated
in FIGS. 2A-2C (from C6, U-87 MG, and U-118 MG gliomas
cell lines, respectively), FIGS. 9A and 9B (PLC and HepG2
hepatocarcinoma cell lines, respectively), and FIGS. 16A
16C (LNCaP. C4-2, and C4-2B human prostate cancer cell
lines, respectively).

50

As described in detail below, in certain embodiments, the

60

cultured cancer cells (e.g., tumor spheroids) produced in chi
tosan-alginate scaffolds by the methods of the invention have
increased tumor malignancy compared to two-dimensionally
cultured cancer cells as well as Matrigel cultured cells. The
cultured cancer cells having increased tumor malignancy are
cancer cells that do not ordinarily show Such malignancy in
2D culture, C6 cells show no increased malignancy because

the methods of the invention have increased CD31" cell

recruitment (i.e., angiogenesis ability) in vivo compared to
two-dimensionally cultured cancer cells as well as Matrigel

cells.

In one embodiment, cultured cancer cells form into aggre
gates known as tumor spheroids. Thus, in one embodiment, a
method for producing tumor spheroids in vitro is provided. In
the method, a porous chitosan-alginate scaffold is seeded
with cancer cells to provide a scaffold comprising cancer

malignant transformation for these cells, is upregulated.
In certain embodiments, the cultured cancer cells (e.g.,
tumor spheroids) produced in chitosan-alginate scaffolds by
the methods of the invention have increased expression of
growth factors (e.g., pro-angiogenic growth factors such as
VEGF, bFGF, and IL-8) compared to two-dimensionally cul
tured cancer cells as well as Matrigel cultured cells.
In certain embodiments, the cultured cancer cells (e.g.,
tumor spheroids) produced in chitosan-alginate scaffolds by
the methods of the invention have increased expression of the
enzyme MMP-2 compared to two-dimensionally cultured
cancer cells as well as Matrigel cultured cells.
In certain embodiments, the cultured cancer cells (e.g.,
tumor spheroids) produced in chitosan-alginate scaffolds by
the methods of the invention have increased expression of the
extracellular matrix proteins (e.g., fibronectin and laminin)
compared to two-dimensionally cultured cancer cells as well
a Matrigel cultured cells.
In certain embodiments, the cultured cancer cells (e.g.,
tumor spheroids) produced in chitosan-alginate scaffolds by
the methods of the invention have increased tumorigenicity in
Vivo compared to two-dimensionally cultured cancer cells as
well as Matrigel cultured cells.
In certain embodiments, the cultured cancer cells (e.g.,
tumor spheroids) produced in chitosan-alginate scaffolds by

the scaffolds does not require any conditions beyond standard
tissue culture conditions. In general, tumor spheroids typi
cally form between 3 and 15 days of culture on the scaffolds.
In another aspect, the invention provides an in vitro can
cerous tumor model, comprising a cancer cells (e.g., tumor
spheroids) cultured in a three-dimensional (3D) scaffold
comprising chitosan and alginate.
In a related aspect of the invention, Scaffolds comprising
cultured cells are provided. In one embodiment, the invention
provides a three-dimensional scaffold comprising a porous
chitosan-alginate scaffold and cultured cancer cells (e.g.,
tumor spheroids). In another embodiment, the scaffold com
prising cultured cancer cells is produced by the method of the
invention.

55

The scaffolds useful in the compositions and methods of
the invention advantageously support cancer cell prolifera
tion and cancerous tumor formation. These scaffolds are

porous scaffolds that include a chitosan and an alginate. In
these scaffolds, the chitosan is ionically linked to the alginate.
In certain embodiments, the scaffolds are further crosslinked

by divalent metal atoms. The porous scaffolds useful in the
compositions and methods of the invention that include chi
tosan and alginate are referred to herein as "chitosan-algi
nate' scaffolds or “CA' scaffolds.

65

Chitosan and alginate are biocompatible, non-mammalian
sourced natural polymers with properties ideal forcell culture
scaffold formation. The chitosan and alginate can be used to
create a 3D interconnected, CA complex porous structure.

US 9,157,908 B2
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Chitosans, natural polysaccharides derived from the partial crosslinked with divalent metal cations. In one embodiment,
deacetylation of chitin, shares structural similarities to gly the ratio of the chitosan to the alginate is from 1:1 to 4:1.
The preparation of suitable chitosan/alginate Scaffolds use
cosaminoglycans present in the native ECM. Chitosans are
linear polysaccharides composed of randomly distributed ful in the methods of the invention are described in Li Z.,
f-(1-4)-linked D-glucosamine (deacetylated unit) and 5 Ramay H. R. Hauch K. D., Xiao D., Zhang M. Chitosan
N-acetyl-D-glucosamine (acetylated unit). Chitosans useful alginate hybrid Scaffolds for bone tissue engineering, Bioma
for making the scaffolds have an average molecular weight terials 2005, 26:3919-3928: Li Z., Zhang M. Chitosan-algi
from about 10 kDa to about 1000 kDa. Generally, scaffolds nate as scaffolding material for cartilage tissue engineering, J
Biomed Mater Res A 2005, 75:485-493; and U.S. Pat. No.
made from higher molecular weight chitosans have greater 10 7,736,669,
expressly incorporated herein by reference in
mechanical strength than scaffolds made from lower molecu its entirety. each
The
preparation
characteristics of a represen
lar weight chitosans. An exemplary range of percentage tative scaffold useful in theandmethods
of the invention are
deacetylation of chitosan useful for making the scaffolds is described in Example 1.
from about 80% to about 100% deacetylation. Alginates area
In a further aspect, the invention provides a method for
family of polyanionic copolymers derived from brown sea 15 producing
a cancerous tumor in a Subject. In the method,
algae. Alginates are linear, 1.4-linked polysaccharides of cultured cells (e.g., tumor spheroids) obtained from the
B-D-mannuronic acid and C-L-guluronic acid. In these scaf method of the invention for producing a scaffold comprising
folds, chitosan is ionically linked to alginate. As used herein, cultured cancer cells are implanted in a Subject. Representa
the term "ionically linked’ refers to a non-covalent chemical tive Subjects include animals such as mice, rats, and dogs.
bond or associative interaction between two ions having
Cultured cancer cells (e.g., tumor spheroids) can be sepa
opposite charges (e.g., electrostatic association between a rated from the scaffold and implanted or the scaffolds com
chitosan amine group and an alginate carboxylic acid group prising cancer cells can be implanted directed. In one embodi
present on alginate).
ment, implanting cultured cells obtained from the method of
The scaffolds comprising chitosan and alginate may be the invention for producing a scaffold comprising cultured
crosslinked to increase their mechanical strength. In one 25 cancer cells, comprises implanting a scaffold comprising cul
embodiment, the porous chitosan/alginate scaffold is tured cancer cells.
Implant of cultured cancer cells (e.g., tumor spheroids) can
crosslinked with divalent metal ions. Thus, in one embodi
ment, in addition to the ionic linkages between chitosan and be done between 1-45 days (or even longer if cells are still
alginate, the scaffolds include ionic linkages formed between growing) of culture on the scaffolds. Time depends on the cell
alginate carboxylic acid groups and divalent metalions (e.g., 30 line and how it responds to culture in the scaffold. Typically,
Ca", Ba'", Mg", Sr"). While not wishing to be bound by cells are implanted after 10 days of culture.
In another aspect of the invention, methods for screening
theory, it is believed that the divalent metal cations form ionic
linkages between adjacent alginate chains, thereby ionically candidate anticancer therapeutic drugs are provided.
crosslinking adjacentalginate molecules.
In one embodiment, the invention provides a method for
In one embodiment, the scaffold further comprises one or 35 screening a candidate chemotherapeutic agent in vitro, com
more growth factors or inhibitory factors effective for cancer prising contacting cultured cells obtained from the method of
the invention for producing a scaffold comprising cultured
cell proliferation and cancerous tumor formations.
Suitable scaffolds have a porosity of from about 85 to about cancer cells with a candidate chemotherapeutic agent. In one
96 percent. In one embodiment, the scaffold has a porosity of embodiment of this method, contacting cultured cells with a
from about 91 to about 95 percent. In another embodiment, 40 candidate chemotherapeutic agent comprises contacting the
the scaffold has a porosity of from about 94 to about 96 candidate chemotherapeutic agent with the scaffold compris
percent.
ing cultured cancer cells.
In vitro drug screening can be conducted between 3-45
Suitable scaffolds have an average pore size diameter of
from about 50 to about 200 um. In one embodiment, the days (or even longer if cells are still growing) of culture on the
scaffold has an average pore size diameter of from about 40 to 45 scaffolds. Typically, cells are cultured for 10 days before in
about 90 m. In another embodiment, the scaffold has an vitro drug screening.
average pore size diameter of from about 60 to about 150 lum.
In one embodiment, the method further comprises measur
In one embodiment, the scaffold has a porosity of from about ing cell proliferation inhibition. In another embodiment, the
85 to about 96 percent and an average pore size diameter of method further comprises measuring the cell viability. In a
50 further embodiment, the method further comprises measur
from about 50 to about 200 um.
The porous scaffold possesses mechanical strength. The ing protein expression levels.
scaffold has a compressive yield strength of at least 0.35 MPa.
In one embodiment, the invention provides a method for
In one embodiment, the scaffold has a compressive yield screening a candidate chemotherapeutic agent in Vivo, com
strength of from about 0.35 MPa to about 0.5 MPa. The prising implanting in a Subject cultured cells obtained from
scaffold has a compressive modulus of from about 5 MPa to 55 the method of the invention for producing a scaffold compris
8 MPa. In one embodiment, the scaffold has a compressive ing cultured cancer cells; and administering a candidate che
yield strength of from about 0.35 MPa to about 0.5 MPa and motherapeutic agent to the Subject. In one embodiment of this
method, implanting cultured cells comprises implanting the
a compressive modulus of from about 5 MPa to 8 MPa.
scaffold comprising cultured cancer cells.
In one embodiment, the scaffold has a porosity of from
about 85 to about 96 percent, an average pore size diameter of 60 Drugs can be administered before tumor implant (tumor
from about 50 to about 200 um, a compressive yield strength vaccine type studies), within 1-2 weeks of implant (growth
of from about 0.35 MPa to about 0.5 MPa, and a compressive inhibition studies), or once the tumor has reached a certain

size, typically 100 mm after 2-8 weeks (cell kill and growth

modulus of from about 5 MPa to 8 MPa.

In one embodiment, the scaffold useful in the invention is

a porous structure comprising a chitosan, an alginate, and
divalent metal cations, wherein the chitosan is ionically
linked to the alginate; and wherein the alginate is further

65

inhibition studies). administering the drug after a pre-deter
mined period of time.
In one embodiment, the method further comprises compar
ing the tumor mass or Volume measured prior to drug admin
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istration and after a pre-determined period of time after drug
administration. In another embodiment, the method further

comprising harvesting the tumor mass after a pre-determined
period of time after drug administration and analyzing the
tumor.

As described herein, in the compositions and methods of
the invention, a biocompatible chitosan-alginate complex
scaffold was used to model the structure of the TME of cancer

cells in vitro. The differences in proliferation rate observed
between 2D, Matrigel matrix, and CA scaffold culture con
ditions can be attributed to the diffusion-limitations imposed
by 3D culture environments. The TME is inherently hetero
geneous, with the cells at the periphery of a tumor mass
receiving the most nutrients and oxygen, while the cells
closer to the center are typically hypoxic, whereas 2D mono
layer cultured cells have no barrier to this exchange. 3D CA
scaffolds allow for cell clusters to formen masse, creating 3D
multicellular microenvironments that permit additional inter
actions between cells that cannot be generated by 2D culture.
Changes in ECM deposition patterns and the ability to form
tight junctions with neighboring cells in the 3D CA scaffold
likely facilitate the formation of these cell clusters. This com
plex arrangement of cells cultured in CA scaffolds resembles
that of multicellular spheroid cultures used to model tumor
behavior.

10
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Further analysis of differently cultured cancer cells
revealed that expression of the angiogenic factors (e.g., IL-8,
bFGF, and VEGF) were elevated in CA scaffold cultured cells
compared to both 2D and Matrigel cultured cells. This sug
gests that the cell-cell and cell-ECM interactions created
upon culture in CA scaffolds more faithfully mimicked the
native TME conditions that regulate angiogenic factor secre
tion. Also, for cultured HCC cancer cells, GPC-3 expression,
which is correlated with poor patient Survival, and is a poten
tial prognostic factor, was significantly elevated in CA cul
tured HepG2 cells. CA scaffolds stimulate the concurrent
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expression of multiple markers for increased malignancy,
consistent within vivo observations, Suggesting that CA Scaf
folds provide microenvironmental cues that neither 2D nor
Matrigel microenvironments simulate faithfully.
The rapid in vivo tumor expansion by the CA scaffold
pre-cultured cells may be a result of the rapid establishment of
neovasculature because the growth factors vital for the
recruitment and maturation of blood vessels were highly
expressed in CA tumor models. The increased pro-angio
genic growth factor secretion by CA scaffold pre-cultured
cells promptly overcame the initial lack of vascularization
within the flank tumor implant providing sufficient nutrients
for rapid tumor formation. As described herein, observed
blood vessel formation in histological sections revealed that
blood vessel morphology and organization varied tremen
dously based on pre-treatment. Extravascular pockets of
bright red erythrocytes associated with poorly formed leaky
vasculature, which is indicative of angiogenesis, were visible
in Matrigel pre-cultured HepG2. CA scaffold pre-cultured
HCC tumors contained large, round, well endothelialized
blood vessels without intraluminal bridging, characteristic of
VEGF induced tumor vasculature. Compared to Matrigel
pre-cultured HepG2 tumors, there were a large number of
erythrocytes in the blood vessel and no notable extravascular
erythrocytes in CA HCC samples. Blood vessel formation
after 4 weeks of in vivo growth correlated well with angio
genic growth factor expression in vitro, Suggesting persistent
phenotypical changes induced by in vitro cell culture condi
tions.

The methods of the invention and the scaffolds provided by
the methods are effective for culturing cancer cells. The
nature of the cancer cell cultured in the compositions and
methods of the invention is not critical. Representative cancer
cell lines that have been cultured in the chitosan-alginate
scaffold and their properties are summarized in Table 1.
TABLE 1

Properties of cancer cell lines cultured in chitosan-alginate scaffolds.
Cell line

Species Disease
Rat

Glioma

U-87 MG

Human

Glioblastoma

Property

Increased tumor spheroid

generation
Increased tumor spheroid
generation, increase
secretion, increase MMP-2
secretion, increase fibronectin
secretion, increased laminin
secretion, enhanced tumorigenicity,

increased resistance to
temozolomide
U-118
MG

Human

Glioblastoma

HepG2

Human

Hepatocellular carcinoma

PLC

Human

Hepatoma

Increased tumor spheroid
generation, increased VEGF
secretion, increased MMP-2
secretion, increased fibronectin
secretion, increased laminin
secretion, enhanced tumorigenicity
Increased tumor spheroid
generation, increased IL-8
secretion, increased bFGF
secretion, increased VEGF
secretion, increased GPC-3
expression, increased resistance to
doxorubicin, enhanced
tumorigenicity
Increased tumor spheroid
generation, increased IL-8
secretion, increased bFGF
secretion, increased VEGF
secretion, increased GPC-3
expression, increased resistance to
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TABLE 1-continued
Properties of cancer cell lines cultured in chitosan-alginate Scaffolds.
Cell line

Species Disease

LNCaP

Human

Property
doxorubicin, enhanced
umorigenicity

Prostate carcinoma

increased tumor spheroid

generation, increased interaction
with PBLS

C4-2

Human Prostate carcinoma (Subline
increased tumor spheroid
generated from LNCaP injected generation, increased interaction

C4-2B

Human Prostate carcinoma (Subline
increased tumor spheroid
generated from bone metastases generation, increased interaction
in LNCaP injected castrated
with PBLS
mice)

TRAMPC2

Mouse

Prostate adenocarcinoma

increased tumor spheroid
generation

SF767

Human

Glioblastoma

increased resistance to
emozolomide

MMC

Mouse Mammary carcinoma

castrated mice)

with PBLS

increased tumor spheroid
generation

The following is a description of representative cancer cell
growth in chitosan-alginate (Calif.) scaffolds in accordance
with the method of the invention.
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Gliomas

Gliomas are the most common and lethal type of brain
cancer, accounting for 80% of brain tumors, with a 2-year
survival of 17-43%. Recent advances in the understanding of
glioma biology have revealed effective therapeutic targets,
translating to improved patient outcomes. Despite these
improvements, the development of anticancer drugs has been
hindered by the lack of effective tumor models that closely
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mimic the human disease.

The present invention demonstrates that CA scaffolds can
be used to better mimic the tumor microenvironment of

glioma in vitro by promoting a more malignant phenotype.
These tumors were developed in vitro by seeding U-87 MG
and U-118 MG human glioma cells on CA scaffolds. As a
comparison, a cancer stem-like cell line (C6 rat glioma),
which is known to be highly invasive and tumorigenic, was
also tested. Developed tumor malignancy was assessed by
ELISA and dot blot analyses of secreted key growth factors

40
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and extracellular matrix. Further assessment of invitro devel

oped U-87 MG tumors was performed by implantation into
mice and monitoring tumor growth and blood vessel forma
tion. In vitro tumors from C6 cells were also implanted as a

50

control.

Glioma Cell Incorporation into CA Scaffolds
CA Scaffolds are prepared by lyophilizing and crosslinking
a physical mixture of chitosanandalginate. The formed Scaf
folds are highly porous to allow for the influx of cells through
out the scaffold, and provide a large Surface area for cell
attachment and proliferation, ideal for modeling the tumor

of solid tumors. Cells in solid tumors exhibit a more rounded
55

Differential Growth Factor Expression in Cells Pre-Cul
tured on CA Scaffolds
60

2

The tumor model was established by seeding U-87 MG and
U-118 MG human glioma cells on the scaffolds and allowing
the tumor cells to proliferate in vitro for 10 days. A control
tumor model was established using C6 ratglioma cells which
have a highly malignant phenotype, and thus should be rela
tively unresponsive to culture conditions.

and interconnected morphology, similar to that seen in cells
grown on CA scaffolds. Therefore, the CA scaffolds are able
to provide a growth environment that promotes the formation
of solid tumor-like cells.

microenvironment.

The preparation of a representative chitosan-alginate Scaf
fold and its seeding with cancer cells is described in Example

Cell incorporation into CA scaffolds was monitored
through proliferation and Scanning Electron Microscopy
(SEM) analyses. All cell lines were able to proliferate within
the CA scaffolds indicating the biocompatibility of the scaf
fold. Cells were also grown on standard 2D culture wells
(24-well plates) and in 3D Matrigel matrix for comparison.
The proliferation of cells grown on CA scaffolds was slightly
retarded compared to 2D and Matrigel cultures (FIG. 1). This
behavior more closely resembles that of tumors in vivo which
grow more slowly than in standard in vitro cell cultures. 2D
cultures Supply cells with unlimited amounts of nutrients and
Sufficient oxygen allowing them to grow rapidly, whereas in
vivo tumors must recruit blood vessels before they can begin
to proliferate rapidly. A slower rate of diffusion of oxygen and
nutrients to cells in the interior of the CA scaffolds may
account for the retarded growth rate observed, whereas nutri
ents and oxygen readily diffuse to the interior of the Matrigel
gel matrix.
To examine cell morphology, SEM images were acquired
of cells grown under the three different conditions (FIG. 2).
All three cell lines displayed altered morphologic phenotypes
dependent on the culture environment. Cells cultured on 2D
wells displayed a linear and elongated morphology, whereas
those grown in the 3D culture condition created by the Matri
gel matrix developed many invadopodia. Glioma cells cul
tured on CA Scaffolds had a more rounded appearance.
Although invadopodia is an indicator of malignancy, this
morphology is seen in invading cells rather than glioma cells
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To determine the effect of 3D culture on the malignant
potential of glioma cells, we performed ELISA analyses on
the secreted growth factor VEGF (FIG. 3A) and the enzyme
MMP-2 (FIG. 3B). Additionally, dot blot analyses were per
formed to quantify the secretion of extracellular matrix
(ECM) proteins, laminin (FIG. 3C) and fibronectin (FIG.
3D). These particular growth factors were evaluated as they
play a significant role in angiogenesis and various other path
ways in glioma which promote growth, invasion, and resis
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over weeks one (P<0.0001, N=6) and two (P<0.0001, N=6)
provides further support that the CA scaffolds were able to

13
tance to chemotherapeutic drugs. Overexpression of these
factors contributes to an increase in cancer malignancy.
VEGF secretion plays a pivotal role in blood vessel recruit
ment to the tumor. As shown in FIG. 3A, VEGF secretion by
C6 cells grown in CA scaffolds was 0.47+0.16 fold (P<0.01,
N=3) lower than those grown on 2D culture wells. U-87 MG

mimic the tumor microenvironment as U-87 MG cells were

able to develop a malignant profile prior to implantation,
allowing for rapid tumor development. However, this rapid
tumor growth was not Sustained; after an initial burst of tumor
growth, the implanted CA Scaffold pre-cultured tumors began
to grow at a similar rate to the 2D and Matrigel pre-cultured

cells in CA scaffolds, on the other hand, showed a 13.98+3.58

fold (P<0.001, N=3) higher VEGF secretion than those on 2D
culture wells. U-118 MG cells in CA scaffolds also showedan

increase in VEGF secretion (1.91+0.50 fold, P-0.01, N=3), as
compared to 2D cultured cells.
MMP-2 breaks down the extracellular matrix to provide
room for cell proliferation and endothelial cell recruitment
for angiogenesis. As shown in FIG.3B, MMP-2 secretion did
not change significantly in C6 cells cultured in CA Scaffolds,
whereas secretion increased 16.24+3.58 fold (P<0.0001,
N=3) in U-87 MG cells and 2.17+0.50 fold (P<0.01, N=3) in
U-118 MG cells cultured in CA scaffolds as compared to 2D

tumors.
10
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showed an enhanced extracellular matrix secretion in tumors

formed from CA scaffold pre-cultured cells (FIG. 5B). This
increased deposition of the extracellular matrix provides fur
ther evidence of higher malignancy in U-87 MG cells cul

cultures.

Fibronectin and laminin equip cells for angiogenesis by
providing a signal and structure for endothelial cell attach
ment and proliferation. Secretion of these extracellular matrix
proteins were not significantly changed in C6 cells cultured in
CA scaffolds as compared to 2D culture wells, shown in
FIGS. 3C and 3D. Fibronectin Secretion increased 3.13-0.13

tured in CA scaffolds.

Angiogenesis in Tumors Formed from CA Scaffold Pre
Cultured Cells
25

fold (P<0.0001, N=4), and laminin secretion increased
1.81+0.01 fold (P<0.0001, N=4) in U-87 MG cells cultured
on CA scaffolds as compared to 2D culture wells. For U-118

A key hallmark of malignant tumor progression is angio
genesis. Xenograft tumors formed from 2D cultured cells,
Matrigel matrix cultured cells, and CA scaffold cultured cells
were photographed in live mice to show vasculature (FIG. 6).
Visible blood vessel formation in C6 tumors was not affected

MG cells cultured on CA scaffolds, fibronectin secretion

increased 2.38+0.57 fold (P<0.001, N=4) and laminin secre
tion increased 5.39+1.19 fold (P<0.0001, N=4) as compared
to 2D culture wells. Matrigel samples were not tested because
they contain both fibronectin and laminin.
From these data it is apparent that CA scaffolds promote
the formation of a more malignant phenotype in human
glioma cell lines as compared to standard 2D and Matrigel
culture conditions. The up-regulation of growth factors
observed upon culture in CA scaffolds indicates these cells
have an enhanced ability to modify their extracellular space,
and are able to create a niche conducive to their progression.
This behavior is more representative of the human glioma

Masson’s trichrome histological analysis of C6 tumors
after 3 weeks of implantation showed no significant changes
in cell morphology or deposition of extracellular matrix
regardless of pre-culture condition (FIG. 5A), which agrees
with the in vitro findings. Masson’s trichrome histological
analysis of U-87 MG tumors 4 weeks following implantation

30

by pre-culture conditions as expected from the similarity in
growth factor expression levels and tumor growth rate (FIG.
6A). Angiogenesis was highly visible in vasculature to U-87
MG tumors from cells pre-cultured in CA scaffolds (FIG.
6B). No blood vessel recruitment was evident around tumors
formed from 2D or Matrigel pre-cultured U-87 MG cells.
Even if blood vessels are not visible on the tumor surfaces,
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endothelial cells can still penetrate the tumor for angiogen
esis. To visualize the recruitment of endothelial cells and

established blood vessels within the tumors, CD31" cells
were visualized using immunohistochemistry (FIG. 7). There
40

was no apparent difference in CD31" cell recruitment in C6
tumors regardless of pre-culture condition (FIG. 7A). Fur
ther, these cells were randomly distributed throughout the

tumor in vivo because cells in vivo must restructure the extra

tumor and lacked blood vessel structure. On the other hand,

cellular matrix and secrete growth factors to promote angio
genesis. As expected, C6 cells were relatively unresponsive to
their environment. This may be due to the fact that this cell
line comprises mainly cancer stem cells which favor the
expression of factors that promote growth and tumorgenicity,
even in standard long-term in vitro growth conditions. The
highly malignant phenotype of C6 cells in standard 2D cul
ture conditions were not further increased upon culture in the
3D environment supplied by either Matrigel matrix or CA

U-87 MG tumors formed from CA scaffold pre-cultured cells
showed a greatly enhanced recruitment of CD31" cells indi
cating an improved ability for angiogenesis (FIG.7B). This is
further corroborated by the numerous circular blood vessel

45

structures visible in these tumors, whereas the tumors formed
50

scaffolds.

Tumorigenesis of Cells Pre-Cultured on CA Scaffolds
To further assess the malignancy of glioma cells cultured in
CA scaffolds as compared to 2D and Matrigel cultures, and to
confirm the increase in malignancy was physiologically rel
evant, the tumorigenicity of U-87 MG cells was determined
by implantation of the pre-cultured matrices into nude mice.
2D, Matrigel, and CA scaffold pre-cultured C6 cells were also
implanted as a control. As anticipated, C6 cells implanted into
mice formed tumors at approximately the same rate regard
less of pre-culture condition (FIG. 4A). This is attributable to
the minimal difference in growth factor and extracellular
matrix secretion in these already highly malignant cells. U-87
MG cells implanted in mice showed a positive correlation
between accelerated tumor growth rate and pre-culture in CA
scaffolds (FIG. 4B). This increased rate of tumor formation

from 2D and Matrigel matrix pre-cultured U-87 MG cells
showed fewer, randomly distributed CD31" cells. This accel
erated rate of structured angiogenesis in tumors formed from
CA scaffold pre-cultured U-87 MG cells can be attributed to
the increased expression levels of growth factors in these
cells, indicating their enhanced malignant potential.
As described above, U-87 MG cells in CA scaffolds exhib

55

ited a slower proliferation rate when cultured invitro (FIG.1),
while CA scaffold cultured U-87 MG cells showed acceler

60

ated tumor growth in vivo (FIG. 4B). The proliferation rate in
vitro is affected by the cells’ ability to acquire the oxygen and
nutrients which diffuse more slowly in CA scaffolds than on
2D culture plates and Matrigel, which resulted in a slower
proliferation rate in CA scaffolds. The tumor growth rate in
vivo is significantly affected by its ability to recruit blood
vessels that provide pathways for biofluid exchange. The
results shown in FIG. 7B further confirms the correlation
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between blood vessel formation and tumor growth rate.
CA scaffolds are able to provide a growth environment for
glioma cells in vitro which is similar to the tumor microen
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Vironment structure encountered in Xenograft tumors in vivo.
This reproducible and easily modifiable experimental system
offers a number of advantages: they can be easily transferred
into mice for rapid Xenograft tumor growth, they can be used
to pre-screen therapies to reduce the amount of in Vivo Screen
ing, and they can be easily degraded to harvest single, viable
cells for analyses such as PCR and flow cytometry. This will
not only reduce the amount of time needed to complete
experiments, but also reduce the enormous costs and loss of
animal life associated with in vivo models.

16
would affect the secretion of growth factors or cytokines that
may stimulate tumor expansion and promote malignancy.
The expansion of malignant tumors has been shown to be
dependent on the development and maintenance of the Sur
rounding vascular network in Vivo, therefore, the expression
of pro-angiogenic growth factors IL-8, bFGF, and VEGF,
secreted by HCC cells, was evaluated using ELISA assays.
IL-8 has been implicated in cell proliferation, invasion, and
recruitment of blood vessels for cancer cell survival. As illus
10

Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most com
mon Solid malignancies with over a million new cases diag
nosed annually worldwide. Most patients with HCC present
in an advanced stage are not amenable to potentially curative
treatments (e.g., orthotopic liver transplantation and Surgical
liver resection). Even the most recent advancements in che
motherapeutics (e.g., Sorafenib) prolong Survival by merely
three month. This result reflects an urgent need for the devel
opment of new and more effective therapies.
Unfortunately, experimental models used to test novel
HCC therapies are limited. Costly in vivo animal models
remain the most sophisticated and faithful models of the

15
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disease.
CA scaffolds were used to mimic the structure of the in

vivo TME of HCC in vitro by inducing a biological response
in the HCC cell lines, PLC/PRF/5 (PLC) and HepG2. This in
vitro HCC tumor model more closely resembles the in vivo
tumor than traditional 2D cell culture or Matrigel, and can be
used as a platform to rapidly evaluate anti-cancer therapies
that will translate better to in vivo studies and promote effec
tive treatment of this deadly disease.
In Vitro Cell Response
In vitro models of hepatocellular carcinoma (HCC) were
generated by culturing human PLC/PRF/5 (PLC) or HepG2
cells in either a 2D surface, Matrigel, or CA scaffold environ
ment. The proliferative response of these cells was compared
using the Alamar Blue assay. As shown in FIGS. 8A and 8B,
Successful expansion and propagation was observed for both
PLC and HepG2 cell lines in all three substrate conditions.
Statistically significant differences in PLC proliferation were
observed at 2 (p<0.01), 4 (p<0.01), 6 (p<0.01) and 8 (p<0.01)
days. Similarly, HepG2 also exhibited statistically significant
changes in proliferation at 2 (p<0.01), 4 (p<0.01), 6 (p<0.01),
8 (p<0.01) days. However, the proliferation rates in 3D cul
ture conditions (i.e., Matrigel and CA Scaffolds were signifi
cantly lower than the rates in the 2D condition).
The effect of the culture microenvironment on cell mor

phology was evaluated by SEM, which showed significant
differences in cell morphology and organization between 2D
and 3D culture conditions for both HCC cell lines (FIGS. 9A
and 9B). PLC cells cultured on a flat monolayer 2D condition
exhibited an elongated morphology, whereas when cultured
in Matrigel, cells exhibited an enlarged spherical morphol
ogy, and clustered together within the provided ECM. This
3D organization of PLC cells was also observed when cul
tured in CA scaffolds, where spherical cells formed large
dense aggregates within the pores of the scaffold. Similarly,
HepG2 cells exhibited a spherical morphology when cultured
in either Matrigel or CA scaffolds, and demonstrated greater
organization by formation of Stacked groupings of cells that
filled the scaffold pores.
Cellular Protein Expression
The protein expression profile of the cultured cells was
examined to determine if the various culture conditions
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trated in FIG. 10A, IL-8 expression was upregulated by both
PLC and HepG2 cells cultured in CA scaffolds, by a factor of
2.86+0.38 fold (p<0.01) and 4.37+0.84 fold (p<0.01), respec
tively, as compared to 2D cultured cells. bFGF is a chemot
actic signal that induces endothelial cell migration, an angio
genic phenotype, stimulating proliferation, and the release of
ECM remodeling enzymes. As shown in FIG. 10B, CA scaf
fold-cultured PLC and HepG2 cells both increased the
expression of bFGF by a factor of 1.83+0.22 fold (p<0.01)
and 3.16+0.81 fold (p<0.01), respectively, as compared to
their 2D counterparts. VEGF is a multi-functional cytokine
that plays an important role in angiogenesis. VEGF expressed
by PLC and HepG2 cells cultured in CA scaffolds was sig
nificantly higher than that of 2D cultured cells, by a factor of
2.28+0.27 fold (p<0.01) and 2.54+0.43 fold (p<0.01), respec
tively (FIG. 10C).
Glypican-3 (GPC-3) is a surface proteoglycan expressed in
up to 83% of HCC's and has been used as a specific marker of
a cells malignant transformation (26-28). HepG2 is knownto
express a high level of this gene, while PLC does not. Dot
blots used to determine the GPC-3 expression level showed
that GPC-3 expression in HepG2 cells cultured in 3D Matri
gel and CA scaffolds was greatly increased, by 2.6+0.37 fold
and 5.5+0.42 fold (p<0.01), respectively, compared to 2D
culture (FIG. 11).
In Vivo Tissue Response
The in vivo tissue response to implantation of HepG2 and
PLC cells pre-cultured in the three in vitro conditions (i.e.,
2D, Matrigel, and CA scaffold cultures) was evaluated in a
Subcutaneous Xenograft model in athymic nude mice. Initial
cell numbers were normalized to the number of cells in CA
scaffold culture. Tumor volumetric measurements over a

four-week period demonstrated significant increases in tumor
size for CA scaffold pre-cultured HCC cells compared to both
2D and Matrigel pre-cultured HCC cells (FIGS. 12A and
12B). CA pre-cultured PLC cells generated final in vivo
tumor Volumes nearly twice as large as that generated by PCL
cells pre-cultured in 2D or Matrigel, while maintaining con
sistent proliferation rates between pre-culture conditions
(FIG. 12A). Statistically significant differences were
observed between PLC cultured samples at 1 (p<0.01), 2
(p<0.01), 3 (p<0.01), and 4 (p<0.01) weeks. Similarly, CA
pre-cultured HepG2 cells expanded to form tumors over four
times the size of 2D cultured cells, and significantly larger
than those pre-cultured in Matrigel, again maintaining con
sistent proliferation rates for this cell line (FIG. 12B), with
statistically significant differences between samples at the 2
(p<0.01), 4 (p<0.01), 6 (p<0.01) and 8 (p<0.01) week time
points as well. The CA pre-cultured cells effected favorable
conditions for tumor expansion in vivo without altering
expansion rates for either HCC cell line.
Tumors were harvested 4 weeks post-implantation, forma
lin-fixed, and sectioned for histological imaging. Hematoxy
lin and eosin staining revealed significant differences in blood
vessel morphology based on pre-culture condition (FIGS.
13A and 13B). Both 2D and Matrigel pre-cultured cells dis
played consistently small and irregularly shaped blood ves
sels with poorly endothelialized thin walls which did not
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consistently delineate the vessel from the Surrounding tissue.
In contrast, CA pre-cultured cells induced the formation of
large, well rounded blood vessels with well-defined endothe
lial linings, carrying large numbers of erythrocytes. Addition
ally, the original porous structure of the CA scaffold was not
observed in the histological samples, indicating the scaffold
is completely removed by the remodeling action of the cells,
confirming the scaffold's excellent biodegradability.
Cellular Response to Chemotherapy
To determine if the in vitro microenvironment is capable of
inducing an environment-mediated drug response in the
tumor models, cell viability in response to doxorubicin treat
ment was evaluated. Cell viability was then assessed over a
72-hour period using the Alamar Blue assay (FIGS. 14A,
14B, 15A, and 15B). Successive viability measurements of
doxorubicin treated cells revealed significantly different
cytotoxic responses between cell types and culture conditions
(FIGS. 14A and 14B). PLC cell viability declined rapidly in
2D culture, with statistically significant differences in cell
viability observed at 24 hours (p<0.01) and 48 hours (p<0.01)

5

10

relevant dose based on the clearance rate of doxorubicin in
15

25

vivo. Overall, CA cultured cells exhibited significantly
greater viability than either 2D or Matrigel cultured cells
when exposed to doxorubicin, Suggesting that the CA
microenvironment induced greater resistance to chemo
therapy. The LDs for doxorubicin treated PLC cells
increased significantly, by nearly twenty times in 3D culture
compared to 2D culture, and for HepG2, tumor models
formed in CA scaffolds had an LDso nearly thirty times
greater than 2D cultured cells. The tumor cell clusters that
formed exclusively upon culture in CA scaffolds reduced the
exposure of the cells to therapeutic agents because diffusion
of therapeutic agents into the tumor mass is limited by the
distance of the core to the Supply, and may induce drug
resistant properties typical to spheroid culture. The upregu
lation of the P-glycoprotein multidrug transporter, strongly
linked to doxorubicin resistance, has been associated with the

the survival of PLC cells based on culture condition became

more apparent, and viability of CA cultured cells was also
observed to be significantly higher than other culture models
in 1 uM (p<0.01), 5 uM (p<0.01), and 10 uM (p<0.01) doxo
rubicin treatments (FIG.15A). Finally, significant differences
in PLC viability between culture conditions was observed 72
hours after 1 uM (p<0.01) doxorubicin treatment (FIG.15A).
In a similar fashion, HepG2 cells also responded differen
tially to doxorubicin dose over time. Differences in HepG2
viability between cell culture conditions were not apparent
until 72 hours post treatment (p<0.01) when treated with 10
uM doxorubicin (FIG. 14B). While the onset of cell death in
HepG2 cells was much less pronounced at 24 and 48 hours
compared to PLC cells, the viability was notably decreased in
2D cultures compared to both Matrigel and CA 3D cultures,
statistically significant differences observed in HepG2 viabil
ity observed at 72 hours when treated with 1 uM (p<0.01), 5
uM (p<0.01), and 10 uM (p<0.01) doxorubicin (FIG. 15B).
Interestingly, at 72 hours, the viability of HepG2 cells cul
tured on CA scaffolds and exposed to 1 uM doxorubicin
increased slightly to 88.6+2.75% compared to 86.7+2.4% at
48 hours (FIG. 15B). The viability measurements indicated
that a population of HepG2 cells cultured in CA scaffolds had

and CA scaffold cultured HCC cells were treated with doxo

rubicin Supplemented media for 24 hours at a physiologically

after treatment between culture conditions when treated with

5uM doxorubicin (FIG. 14A). After 24 hours of drug induc
tion, a differential, dose-dependent Survival response was
observed where viability of 2D cultured PLC cells was sig
nificantly lower than either Matrigel or CA cultured cells after
treatment with 1 uM (p<0.01), 5 uM (p<0.01), and 10 uM
(p<0.01) doxorubicin (FIG.15A). At 48 hours, differences in
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The microenvironment conditions produced in the CA
tumor models induced significant changes in cellular behav
ior as compared to conventional 2D culture environments.
Doxorubicin is an anthracyline antibiotic that induces apop
tosis in HCC by intercalating DNA and interfering with topoi
somerase II DNA replication. Doxorubicin is a cytotoxic
agent commonly incorporated in catheter-based therapies for
metastatic disease, ideal for measuring and comparing
response of systemic therapies against HCC. 2D, Matrigel,
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3D tumor microenvironment and also likely contributed to
observed doxorubicin resistance. Additionally, hypoxic con
ditions at the core of the tumor cluster may trigger cell qui
escence, making these cells less susceptible to the action of
doxorubicin that interrupts the cell cycle during DNA repli
cation. This was confirmed by the elevated levels ofbFGF and
VEGF expression, which have been associated with interca
lating agent resistant quiescent tumor phenotypes, in CA
HCC tumor models. Finally, GPC-3 over-expression, which
has been implicated in the increased resistance to topoi
Somerase II inhibitors such as doxorubicin, was displayed by
HepG2 cells cultured in CA scaffolds. The greatly increased
resistance of 3D CA HCC tumor models to chemotherapy
more closely resembles the in vivo levels of resistance, where
standard dosing schemes result in peak plasma concentra
tions of approximately 15 uM doxorubicin minutes after
treatment, declining to nearly complete clearance at 48 hours
post treatment. The CA scaffolds were shown to be capable of
stimulating cooperative signaling between cells and the envi
ronment that led to the expression of a highly malignant, drug
resistant phenotype.
The following examples are provided for the purpose of
illustrating, not limiting, the invention.

survived doxorubicin treatment that had eliminated cells cul

tured on 2D plates.
The LDs of a drug is defined as the median lethal dose and
commonly used as a measure of the effectiveness of a drug in
inhibiting biological or biochemical function. The LDs of
doxorubicin in each of the conditions was evaluated post
induction, where both HCC cell types displayed significant
differences in cell viability across culture conditions (FIGS.
15A and 15B). The LDs of doxorubicin was 0.2+0.13 uM for
PLC cells cultured on 2D surfaces, 3+1.1 uM for Matrigel
cultured, and 4+1.4LMCA cultured cells as determined at 72
hours post treatment (FIG. 15A). Similarly, the LDs for
doxorubicin treated HepG2 cells cultured in 2D substrate was
0.45+0.18 uM, increasing to 7+2.2 LLM in Matrigel, and
finally to 13+1.7 uM in CA at 72 hours post treatment (FIG.
15B).

EXAMPLES

Materials and Methods

55

Materials.
60

65

All chemicals were purchased from Sigma-Aldrich (St.
Louis, Mo.) unless otherwise specified. Chitosan (Poly
Sciences, Pa., 15,000 MW) and sodium alginate powders
were used as received. Antibiotic-antimycotic, Dulbecco's
Modified Eagle Medium (DMEM), Antibiotic-antimycotic,
Dulbecco's phosphate buffered saline (D-PBS), and Alamar
Blue reagent were purchased from Invitrogen (Carlsbad,
Calif.). Fetal bovine serum (FBS) was purchased from
Atlanta Biologicals (Atlanta, Ga.). C6 ratglioma, U-87 MG
human glioma, and U-118 MG human glioma cell lines, and
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PLC/PRF/5 (PLC) and HepG2 human hepatocellular carci
noma cell lines, and Minimum Essential Media (MEM) were
purchased from American Type Culture Collection (ATCC,
Manassas, Va.). Cells were maintained according to manu
facturers instructions in fully supplemented DMEM (C6 and
U-118 MG) or MEM (U-87 MG) with 10% FBS and 1%
antibiotic-antimycotic) at 37° C. and 5% CO, in a fully
humidified incubator. Reduced growth factor Matrigel matrix
was purchased from BD Biosciences (San Jose, Calif.).
VEGF and MMP-2 ELISA kits were purchased from R&D
Systems (Minneapolis, Minn.). PVDF membrane and
Immun-star chemiluminescent reagent for dot blotting were
purchased from BioRad (Hercules, Calif.), while antibodies
were purchased from Abcam (Cambridge, Mass.).
Cell Proliferation Analysis.
Proliferation of cells cultured on 2D wells, Matrigel
matrix, and CA Scaffolds was determined using the Alamar
Blue assay following the manufacturer's protocol. Briefly,

20
serum counterpart (media containing 1% FBS and 1% anti
biotic-antimycotic) and cells were incubated for 24 hrs.
Media were collected and stored at -80° C. for future use.

Growth factor (bFGF, IL-8, and VEGF) secretion was deter
mined via ELISA assays following the manufacturer's pro
tocol. The protein concentration per cell was calculated based
on cell number in the well, and the values were normalized to
10

In Vivo Studies.

15

cells cultured on 2D wells and 3D scaffolds were washed with

D-PBS before adding 1 mL of Alamar Blue solution (10%
Alamar Blue in fully supplemented phenol red free DMEM or
MEM) to each well.
Forglioma cells, after 1.5 hrs the Alamar Blue solution was
transferred to a 96-well plate to obtain absorbance values on
a microplate reader. The cell number was calculated based on
standard curves created previously. Cells were again washed
with D-PBS to remove Alamar Blue solution and fresh fully
Supplemented media was added to each well.
For human hepatocellular carcinoma cells, after 2 hrs the
Alamar Blue solution was transferred to a 96-well plate to
obtain fluorescent values on a SpectraMax M2 microplate
reader (Molecular Devices, Sunnyvale, Calif.) at 550 nm.
excitation, 590 nm emission. Standard curves were generated
by seeding cells counted using a hemocytometer onto cell
culture materials in triplicate, and performing Alamar Blue
assay to generate a plot of linear regression of fluorescent
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ellipsoid, volume-lengthx(width)xt/6, for 2D and Matrigel
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implantation for C6 and U-87 MG tumors, respectively, mice
were sacrificed by CO, inhalation followed by cervical dis
location, and the tumors were resected, fixed in a 10% for
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cervical dislocation, and the tumors were resected, fixed in a

10% formalin solution, and submitted for histological analy

50

Growth Factor and Extracellular Matrix Secretion Analy
55

were incubated for 24 hrs. Media were collected and stored at
-80° C. for future use. VEGF and MMP-2 secretion was
60

the well, and the values were normalized to 2D culture con

ditions. Laminin and fibronectin were detected using dot blot
analyses and protein concentration per cell was normalized to
2D culture conditions using Image.J.
For human hepatocellular carcinoma cells, after 9 days of
culture, media from cell cultures were replaced with a low

using the formula of a cylinder, i.e., volume-radius'xheightx
it, subtracting initial dimensions of the scaffold (265 mm),
and the formula for an ellipsoid volume (22)
(volume-lengthxwidth x1/6) was used for 2D and Matrigel

SCS.

S1S.

determined following the manufacturer's protocol, protein
concentration per cell was calculated based on cell number in

malin Solution, and Submitted for histological analyses.
For human hepatocellular carcinoma cell-containing scaf
folds, four mice were tested per group. CA scaffold tumors
were measured using calipers and Volume was calculated

tumors. 4 weeks post-implantation of PLC and HepG2
tumors, mice were sacrificed by CO inhalation followed by

cells and Substrate.

After 7 and 9 days of culture for C6 and both U-87 MG and
U-118 MG cells, respectively, media of differently cultured
cells were replaced with a low serum counterpart (media
containing 1% FBS and 1% antibiotic-antimycotic) and cells

tracting the volume of an empty scaffold (265 mm) from the
calculated tumor volume. After 3 weeks and 4 weeks of

were added to each well.

Cellular Morphology Analysis by SEM.
Samples for SEM analysis were first fixed with cold Kar
novsky's fixative overnight followed by dehydration in a
series of ethanol washes (0%, 50%, 75%, 90%, 100%).
Samples were critical point dried and sputter coated with
platinum before imaging with a JSM 7000 SEM (JEOL,
Tokyo, Japan). False color was added to SEM images using
Adobe Photoshop in order to improve the contrast between

All animal studies were performed in accordance with
University of Washington IACUC approved protocols. Athy
mic nude male mice (nu/nu,088 strain, Charles River, Wilm
ington, Mass.) 6-8 weeks of age were anesthetized with a
solution of ketamine and xylazine before CA scaffolds con
taining cells were implanted Subcutaneously into the left and
right flank. 2D and Matrigel matrix pre-treated cells were
diluted into 100 uL media to a cell number matching that on
the CA scaffolds as determined by Alamar Blue assay, and
mixed with 100 uL Matrigel before injecting subcutaneously
into the left and right flanks of the anesthetized mice.
For gliomas cell-containing scaffolds, tumors were mea
Sured using calipers and the Volume was calculated using the
formula of a cylinder, volume-lengthxwidthxheightxt/4, for
CA scaffold tumors (cell-CA scaffold construct has an cylin
drical shape), and using the formula for the Volume of an
tumors. CA scaffold tumor sizes were normalized by sub

values vs. cell number for each material. The cell number in

an experimental sample was calculated based on the standard
curve. No background fluorescence was generated by CA
scaffolds. Cells were again washed with D-PBS to remove
Alamar Blue solution and fresh fully-supplemented media

2D culture conditions. Glypican-3 was detected usingdot blot
analysis and protein concentration per cell was normalized to
2D culture conditions using Image.J (NIH, Bethesda, Md.).

65

Immunohistochemistry.
Excised tumors were embedded in optimal cutting tem
perature (OCT) compound and frozen on dry ice. The frozen
tumor tissue sections (8 um) were washed thrice with PBS to
remove excess OCT compound and fixed for 10 min inform
aldehyde. CD31" cells were stained with an anti-mouse CD31
primary antibody (Abcam, Cambridge, Mass.) and visualized
with an anti-goat IgG FITC conjugated secondary antibody
(Abcam, Cambridge, Mass.) following the manufacturers
protocol. The slides were counterstained with 4,6-diamidino
2-phenylindole (DAPI) in mounting medium (ProLong Gold,
Invitrogen, Carlsbad, Calif.) and imaged using a Zeiss LSM
510 confocal microscope.
Cellular Response to Chemotherapeutic Agents.
For human hepatocellular carcinoma cell-containing scaf
folds, after 10 days of culture, media from cell cultures were
replaced with 1 mL fully supplemented cell culture media
containing various concentrations of doxorubicin. Cells were
induced with doxorubicin containing media for 24 h, after
which media was replaced with standard fully supplemented
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cell culture media. Cell viability was assessed using the
Alamar Blue assay following the manufacturer's protocolas
described above. LDso was estimated via a polynomial
approximation.
Statistical Analysis.
Acquired data are expressed as meantSD. Statistical sig
nificance was determined by one-way analysis of variance
(ANOVA) and Student's t test. Values of P-0.01 were con
sidered significant.
For cellular response to chemotherapeutics, all experi
ments were performed in quadruplicate (n=4). Data are pre
sented as meansistandard deviation. Statistical analysis at
each sampling point was performed using one-way analysis
of variance (ANOVA) comparing each treatment condition.
Differences were considered significant for p-0.05.
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The embodiments of the invention in which an exclusive

property or privilege is claimed are defined as follows:
1. A three-dimensional scaffold, comprising:
(a) a porous chitosan-alginate scaffold; and
(b) cultured cancer cells,
wherein the cancer cells are seeded on the scaffold and are

cultured for a time sufficient to produce tumor sphe
roids.
10

15

5. The scaffold of claim 1, wherein the cultured cancer cells
6. The scaffold of claim 1, wherein the cultured cancer cells

have increased tumorigenicity in vivo compared to two-di
mensionally cultured cancer cells.
25

7. The scaffold of claim 1, wherein the cultured cancer cells

30

have increased CD31" cell recruitment in vivo compared to
two-dimensionally cultured cancer cells.
8. A method for producing a cancerous tumor in a subject,
comprising implanting in a subject the scaffold of claim 1,
and growing the cancer cells for a sufficient amount of time to
produce a cancerous tumor in said subject.
9. A method for screening a candidate chemotherapeutic
agent in vitro comprising contacting in vitro the scaffold of
claim 1 with a candidate chemotherapeutic agent and mea

35

remove any excess salt, and sterilized in 70 v% ethanol for 1
tion and placed on an orbital shaker for about 12hrs to remove
any excess ethanol.
Cells were seeded onto PBS damp CA scaffolds in 24-well

40

plates at 50,000 cells per scaffoldin50 ul fully supplemented
media. Cells were allowed to infiltrate the scaffold for 1 hr

before 1 mL fully supplemented media was added to each
well. For Matrigel pre-cultured samples, 50,000 cells in 200
uL fully supplemented media was mixed with 200 uL Growth
Factor Reduced Matrigel matrix to form a viscous liquid and
added to 24-well plate wells to gel in situ. Samples were
allowed to gel for 1 hr before 1 mL fully supplemented media
was added to each well. For 2D pre-cultured samples, 50,000
cells in 1 mL fully supplemented media were added to
24-well plate wells. Media were replaced every 2 days.
While illustrative embodiments have been illustrated and

described, it will be appreciated that various changes can be
made therein without departing from the spirit and scope of
the invention.

4. The scaffold of claim 1, wherein the cultured cancer cells

have increased expression of the extracellular matrix proteins
compared to two-dimensionally cultured cancer cells.

under vacuum, washed with deionized water several times to

hr. The scaffolds were then transferred to a sterile PBS solu

have increased expression of growth factors compared to
two-dimensionally cultured cancer cells.
have increased expression of the enzyme MMP-2 compared
to two-dimensionally cultured cancer cells.

The Preparation and Seeding of a Representative
Chitosan-Alginate Scaffold

Briefly, a 4 wt % chitosan and 2 wt % acetic acid solution
was mixed under constant stirring in a blender for 7 minutes
to obtain a homogeneous chitosan solution. A 4 wt % alginate
Solution was added to the chitosan solution, and mixed in a
blender for 5 minto obtain a homogeneous CA solution. The
CA solution was cast in 24-well cell culture plates and frozen
at -20° C. for 8 hrs. The samples were then lyophilized,
optionally sectioned into disks of 13 mm diameterx2 mm
thickness, crosslinked in 0.2M CaCl solution for 10 minutes

have increased tumor malignancy compared to two-dimen
sionally cultured cancer cells.
3. The scaffold of claim 1, wherein the cultured cancer cells

Example 1

Chitosan-alginate (Calif.) scaffolds were prepared as
described in Li Z., Ramay H. R. Hauch K. D., Xiao D., Zhang
M. Chitosan-alginate hybrid scaffolds for bone tissue engi
neering. Biomaterials 2005, 26:3919-3928: Li Z., Zhang M.
Chitosan-alginate as scaffolding material for cartilage tissue
engineering, J Biomed Mater Res A 2005, 75:485-493; and
U.S. Pat. No. 7,736,669, expressly incorporated herein by
reference in its entirety.

2. The scaffold of claim 1, wherein the cultured cancer cells
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Suring growth of the cancer cells, wherein a decrease in

growth of said cancer cells in said scaffold as compared to a
control identifies said agent as a chemotherapeutic agent.
10. The method of claim 9, wherein measuring growth of
the cancer cells comprises measuring cell proliferation or
measuring cell viability in said cancer cells.
11. A method for screening a candidate chemotherapeutic
agent in Vivo comprising: (a) implanting in a subject the
Scaffold of claim 1; (b) administering a candidate chemo
therapeutic agent to said subject; and (c) measuring growth of
the cancer cells, wherein a decrease in growth of said cancer
cells in said scaffold as compared to a control identifies said
agent as a chemotherapeutic agent.
12. The method of claim 11, wherein prior to administering
the candidate chemotherapeutic agent to said subject the can
cer cells of said scaffold grow for a sufficient amount of time
to produce a tumor, wherein said measuring growth of the
cancer cells encompasses measuring mass or volume of the
tumor both prior to and after administering the candidate
chemotherapeutic agent; and wherein said control is the mea
Sured mass or Volume of the tumor prior to administering the
candidate chemotherapeutic agent.
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